Regardless, our results are of substantial interest because over 70% of cases of axonal CMT are associated with pathogenic MFN2 variants, and to date, no disease-modifying therapies are available for any genetic subtype of CMT (Yoshimura et al., 2019; Pisciotta et al., 2021). Here, MFN2 is linked to Charcot-Marie-Tooth disease.